Gajewski TF - Search Results

1

Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 3rd-5th, 2020, Italy).

Ascierto PA, Blank C, Dummer R, Ernstoff MS, Ferrone S, Fox BA, Gajewski TF, Garbe C, Hwu P, Kalinski P, Krogsgaard M, Lo RS, Luke JJ, Neyns B, Postow MA, Quezada SA, Teng MWL, Trinchieri G, Testori A, Caracò C, Osman I, Puzanov I, Thurin M. Ascierto PA, et al. Among authors: gajewski tf. J Transl Med. 2021 Jun 30;19(1):278. doi: 10.1186/s12967-021-02951-x. J Transl Med. 2021. PMID: 34193182 Free PMC article.

2

Cutting edge: targeted ligation of CTLA-4 in vivo by membrane-bound anti-CTLA-4 antibody prevents rejection of allogeneic cells.

Hwang KW, Sweatt WB, Brown IE, Blank C, Gajewski TF, Bluestone JA, Alegre ML. Hwang KW, et al. Among authors: gajewski tf. J Immunol. 2002 Jul 15;169(2):633-7. doi: 10.4049/jimmunol.169.2.633. J Immunol. 2002. PMID: 12097362

3

Absence of programmed death receptor 1 alters thymic development and enhances generation of CD4/CD8 double-negative TCR-transgenic T cells.

Blank C, Brown I, Marks R, Nishimura H, Honjo T, Gajewski TF. Blank C, et al. Among authors: gajewski tf. J Immunol. 2003 Nov 1;171(9):4574-81. doi: 10.4049/jimmunol.171.9.4574. J Immunol. 2003. PMID: 14568931

4

PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells.

Blank C, Brown I, Peterson AC, Spiotto M, Iwai Y, Honjo T, Gajewski TF. Blank C, et al. Among authors: gajewski tf. Cancer Res. 2004 Feb 1;64(3):1140-5. doi: 10.1158/0008-5472.can-03-3259. Cancer Res. 2004. PMID: 14871849

5

Negative regulation of T-cell function by PD-1.

Zha Yy, Blank C, Gajewski TF. Zha Yy, et al. Among authors: gajewski tf. Crit Rev Immunol. 2004;24(4):229-37. doi: 10.1615/critrevimmunol.v24.i4.10. Crit Rev Immunol. 2004. PMID: 15588223 Review.

6

Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy.

Blank C, Gajewski TF, Mackensen A. Blank C, et al. Among authors: gajewski tf. Cancer Immunol Immunother. 2005 Apr;54(4):307-14. doi: 10.1007/s00262-004-0593-x. Epub 2004 Dec 15. Cancer Immunol Immunother. 2005. PMID: 15599732 Free PMC article. Review.

7

ICAM-1 contributes to but is not essential for tumor antigen cross-priming and CD8+ T cell-mediated tumor rejection in vivo.

Blank C, Brown I, Kacha AK, Markiewicz MA, Gajewski TF. Blank C, et al. Among authors: gajewski tf. J Immunol. 2005 Mar 15;174(6):3416-20. doi: 10.4049/jimmunol.174.6.3416. J Immunol. 2005. PMID: 15749875

8

Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro.

Blank C, Kuball J, Voelkl S, Wiendl H, Becker B, Walter B, Majdic O, Gajewski TF, Theobald M, Andreesen R, Mackensen A. Blank C, et al. Among authors: gajewski tf. Int J Cancer. 2006 Jul 15;119(2):317-27. doi: 10.1002/ijc.21775. Int J Cancer. 2006. PMID: 16482562 Free article.

9

Innovations and challenges in melanoma: summary statement from the first Cambridge conference.

Atkins MB, Elder DE, Essner R, Flaherty KT, Gajewski TF, Haluska FG, Hwu P, Keilholz U, Kirkwood JM, Mier JW, Ross MI, Slingluff CL, Sondak VK, Sosman JA, Weinstock MA, King L. Atkins MB, et al. Among authors: gajewski tf. Clin Cancer Res. 2006 Apr 1;12(7 Pt 2):2291s-2296s. doi: 10.1158/1078-0432.CCR-05-2560. Clin Cancer Res. 2006. PMID: 16609047

10

Homeostatic proliferation as an isolated variable reverses CD8+ T cell anergy and promotes tumor rejection.

Brown IE, Blank C, Kline J, Kacha AK, Gajewski TF. Brown IE, et al. Among authors: gajewski tf. J Immunol. 2006 Oct 1;177(7):4521-9. doi: 10.4049/jimmunol.177.7.4521. J Immunol. 2006. PMID: 16982889

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

309 results

Search Page